Shares of Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) declined -1.448% and ended at $5.105 smaller than previous closing price of $5.180. The total 876.17 thousand shares were bought and sold throughout the most recent trading session less than average volume of 1.07 million shares.
Currently () captured an average recommendation of “ Buy ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “2″ Analysts”. “0” rated “Sell” for the company. “0” said the company as a “Hold”. Overweight rating was given by “1” and Underweight rating was given by “0”.
Analysts are expecting that the company to achieve $10.50 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $12.00 however minimum price target advised by analysts is $9.50. The Median price target for the stock is measured at $10.00.
Presently, Analysts decided consensus EPS estimate of $-0.29 for present quarter and one month ago projected EPS estimate was at $-0.29. If we take a look at back 3 month ago, consensus EPS estimate was $-0.27.
A current consensus EPS estimate for next quarter is at $-0.35 and 3 month ago EPS forecast was $-0.30. Have a look at back 1 month ago, consensus EPS forecast was seen at $-0.35.
For current fiscal year, most recent EPS estimate is set at $-1.16 based on Analyst consensus and three month ago consensus EPS opinions was at $-1.14. During period one month ago, consensus EPS forecast was decided at $-1.16.
A current consensus EPS projection for next fiscal year is observed at $-0.78 and one month ago consensus EPS forecast was at $-0.78. Take a look at back three month ago, consensus EPS estimate opinions was decided at $-0.69 by analysts.
One Month ago, the stock has gained consensus mean rating of Buy based on the analysis of brokerage analyst firms polled. 2 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 1. 0 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 0.
Three Months Ago, Analysts recommended an average brokerage rating of Buy derived from brokerage firms, according to FactSet. 3 said a “Buy Rating” and 1 announced “Overweight Rating”. 0 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 0 disclosed “Underweight Rating”.